These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

890 related articles for article (PubMed ID: 32213540)

  • 41. FDA Approval Summary: Fam-Trastuzumab Deruxtecan-Nxki for the Treatment of Unresectable or Metastatic HER2-Positive Breast Cancer.
    Narayan P; Osgood CL; Singh H; Chiu HJ; Ricks TK; Chiu Yuen Chow E; Qiu J; Song P; Yu J; Namuswe F; Guiterrez-Lugo M; Hou S; Pierce WF; Goldberg KB; Tang S; Amiri-Kordestani L; Theoret MR; Pazdur R; Beaver JA
    Clin Cancer Res; 2021 Aug; 27(16):4478-4485. PubMed ID: 33753456
    [TBL] [Abstract][Full Text] [Related]  

  • 42. In Vivo and In Vitro Efficacy of Trastuzumab Deruxtecan in Uterine Serous Carcinoma.
    Mutlu L; Manavella DD; Bellone S; McNamara B; Harold JA; Mauricio D; Siegel ER; Buza N; Hui P; Hartwich TMP; Yang-Hartwich Y; Demirkiran C; Verzosa MSZ; Altwerger G; Ratner ES; Huang GS; Clark M; Andikyan V; Azodi M; Dottino PR; Schwartz PE; Santin AD
    Mol Cancer Ther; 2023 Dec; 22(12):1404-1412. PubMed ID: 37676984
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer.
    Rugo HS; Bianchini G; Cortes J; Henning JW; Untch M
    ESMO Open; 2022 Aug; 7(4):100553. PubMed ID: 35964548
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The Potential of Trastuzumab Deruxtecan as a Tissue Agnostic Drug.
    Jørgensen JT
    Oncology; 2023; 101(12):836-842. PubMed ID: 37651992
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical benefit of post-trastuzumab deruxtecan treatment in patients with HER 2-positive unresectable or metastatic breast cancer: A single-institution retrospective observational study.
    Isogai A; Nozawa K; Nakakami A; Komaki R; Ozaki Y; Endo Y; Kataoka A; Kotani H; Yoshimura A; Hattori M; Sawaki M; Iwata H
    Breast Cancer Res Treat; 2024 Sep; 207(2):253-261. PubMed ID: 38797792
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The emergence of targeted therapy for HER2-low triple-negative breast cancer: a review of fam-trastuzumab deruxtecan.
    Schreiber AR; O'Bryant CL; Kabos P; Diamond JR
    Expert Rev Anticancer Ther; 2023; 23(10):1061-1069. PubMed ID: 37742278
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The Future of HER2-Targeted Treatment for Osteosarcoma: Lessons from the Negative Trastuzumab Deruxtecan Results.
    Nakano K
    Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38069146
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical Practices and Institutional Protocols on Prophylaxis, Monitoring, and Management of Selected Adverse Events Associated with Trastuzumab Deruxtecan.
    Bardia A; Harnden K; Mauro L; Pennisi A; Armitage M; Soliman H
    Oncologist; 2022 Aug; 27(8):637-645. PubMed ID: 35642907
    [TBL] [Abstract][Full Text] [Related]  

  • 49. 3D layered co-culture model enhances Trastuzumab Deruxtecan sensitivity and reveals the combined effect with G007-LK in HER2-positive non-small cell lung cancer.
    Shiraishi A; Oh-Hara T; Takahashi Y; Uchibori K; Nishio M; Katayama R
    Biochem Biophys Res Commun; 2024 Sep; 725():150255. PubMed ID: 38897043
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Empower the Potential of Trastuzumab Deruxtecan with Novel Combinations.
    Rolfo C; Del Re M; Russo A
    Clin Cancer Res; 2023 Nov; 29(21):4317-4319. PubMed ID: 37656059
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Safety profile of trastuzumab deruxtecan in advanced breast cancer: Expert opinion on adverse event management.
    Ciruelos E; García-Sáenz JÁ; Gavilá J; Martín M; Rodríguez CA; Rodríguez-Lescure Á
    Clin Transl Oncol; 2024 Jul; 26(7):1539-1548. PubMed ID: 38336982
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Trastuzumab deruxtecan in human epidermal growth factor receptor 2-positive breast cancer brain metastases: a systematic review and meta-analysis.
    Michelon I; Vilbert M; Marinho AD; Castro CER; Dacoregio MI; Stecca C; Soares LR; Batista MV; Braga S; Saeed A; Cavalcante L
    ESMO Open; 2024 Feb; 9(2):102233. PubMed ID: 38320430
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Preclinical and Clinical Efficacy of Trastuzumab Deruxtecan in Breast Cancer Brain Metastases.
    Kabraji S; Ni J; Sammons S; Li T; Van Swearingen AED; Wang Y; Pereslete A; Hsu L; DiPiro PJ; Lascola C; Moore H; Hughes M; Raghavendra AS; Gule-Monroe M; Murthy RK; Winer EP; Anders CK; Zhao JJ; Lin NU
    Clin Cancer Res; 2023 Jan; 29(1):174-182. PubMed ID: 36074155
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Novel HER2-Targeting Antibody-Drug Conjugates of Trastuzumab Beyond T-DM1 in Breast Cancer: Trastuzumab Deruxtecan(DS-8201a) and (Vic-)Trastuzumab Duocarmazine (SYD985).
    Xu Z; Guo D; Jiang Z; Tong R; Jiang P; Bai L; Chen L; Zhu Y; Guo C; Shi J; Yu D
    Eur J Med Chem; 2019 Dec; 183():111682. PubMed ID: 31563805
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Trastuzumab deruxtecan in previously treated HER2-positive metastatic breast cancer: Plain language summary of the DESTINY-Breast01 study.
    Modi S
    Future Oncol; 2021 Sep; 17(26):3415-3423. PubMed ID: 34263665
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial.
    Mosele F; Deluche E; Lusque A; Le Bescond L; Filleron T; Pradat Y; Ducoulombier A; Pistilli B; Bachelot T; Viret F; Levy C; Signolle N; Alfaro A; Tran DTN; Garberis IJ; Talbot H; Christodoulidis S; Vakalopoulou M; Droin N; Stourm A; Kobayashi M; Kakegawa T; Lacroix L; Saulnier P; Job B; Deloger M; Jimenez M; Mahier C; Baris V; Laplante P; Kannouche P; Marty V; Lacroix-Triki M; Diéras V; André F
    Nat Med; 2023 Aug; 29(8):2110-2120. PubMed ID: 37488289
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A Review of Fam-Trastuzumab Deruxtecan-nxki in HER2-Positive Breast Cancer.
    Nguyen X; Hooper M; Borlagdan JP; Palumbo A
    Ann Pharmacother; 2021 Nov; 55(11):1410-1418. PubMed ID: 33629601
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: The DEBBRAH trial.
    Pérez-García JM; Vaz Batista M; Cortez P; Ruiz-Borrego M; Cejalvo JM; de la Haba-Rodriguez J; Garrigós L; Racca F; Servitja S; Blanch S; Gion M; Nave M; Fernández-Abad M; Martinez-Bueno A; Llombart-Cussac A; Sampayo-Cordero M; Malfettone A; Cortés J; Braga S
    Neuro Oncol; 2023 Jan; 25(1):157-166. PubMed ID: 35639825
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Chinese expert consensus on the management of clinical pathway and adverse events of trastuzumab deruxtecan (2024 edition)].
    Trastuzumab Deruxtecan Clinical Management Pathway and Adverse Reaction Management Consensus Expert Group
    Zhonghua Zhong Liu Za Zhi; 2024 Apr; 46(4):304-318. PubMed ID: 38644266
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Trastuzumab Deruxtecan: A Review in Unresectable or Metastatic HER2-Positive Breast Cancer.
    Nie T; Blair HA
    Target Oncol; 2023 May; 18(3):463-470. PubMed ID: 37129796
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 45.